Krystal Biotech (KRYS) Cost of Revenue (2023 - 2026)

Krystal Biotech's Cost of Revenue history runs 4 years deep, the most recent figure standing at $6.3 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 25.76% year-over-year to $6.3 million; the TTM figure through Mar 2026 stood at $24.3 million (up 7.38% YoY), while the FY2025 annual figure was $23.0 million, up 14.89% from the prior year.
• Cost of Revenue came in at $6.3 million for Q1 2026 at Krystal Biotech, down from $6.6 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $7.2 million in Q2 2025 to a low of $223000.0 in Q3 2023.
• A 4-year average of $4.8 million and a median of $5.0 million in 2025 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue soared 2897.31% in 2024 and plunged 36.22% in 2025, its largest moves.
• Krystal Biotech's Cost of Revenue stood at $2.9 million in 2023, then jumped by 72.38% to $4.9 million in 2024, then jumped by 33.2% to $6.6 million in 2025, then decreased by 4.08% to $6.3 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $6.3 million, $6.6 million, and $4.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison